StockData

Amgen vs Biogen

AMGN and BIIB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMGN and BIIB compare

Amgen is the larger company, worth 6.7 times as much as Biogen ($248B against $37.1B).

On earnings, Amgen is cheaper: it trades at 26.5× trailing earnings, against 107× for Biogen.

Amgen grew revenue faster over the last twelve months (8.2% versus 2.3% for Biogen).

Amgen keeps more of each dollar of sales as profit, with a net margin of 24.1% compared with 3.4% at Biogen.

Amgen pays a dividend yielding 2.2%; Biogen does not pay one.

Amgen scores higher on the StockData Score (17 against 4 for Biogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMGNBIIB
Size and price
Market cap$248B$37.1B
Share price$457.93$250.79
Change, 1 year36.0%49.7%
Change, 5 years128%3.2%
Beta (5Y)0.320.14
Employees32K7,500
StockData Score
Total score17 (better)4
Valuation score01 (better)
Growth score5 (better)0
Performance score6 (better)1
Health score22
Dividend score4 (better)0
Valuation
P/E26.5× (better)107×
P/S6.4×3.6× (better)
P/B17.3×–
EV/EBITDA18.8× (better)21.9×
P/FCF25.8×17.9× (better)
PEG4.81–
FCF yield3.9%5.6% (better)
Fair value$364.40$160.54
Margin of safety−25.7% (better)−56.2%
Growth
Revenue growth (TTM)8.2% (better)2.3%
Revenue growth, 5Y average7.6% (better)−6.0%
Net income growth (TTM)34.1% (better)−78.4%
EPS growth (TTM)33.3% (better)−78.7%
EPS growth, 5Y average2.9% (better)−18.7%
Profitability
Gross margin70.9%74.0% (better)
Operating margin32.4%–
Net margin24.1% (better)3.4%
FCF margin24.6% (better)20.1%
Return on equity78.4%–
Return on invested capital19.5%–
Financial health
Debt / equity3.76–
Net debt / EBITDA2.67–
Interest coverage4.8×–
Current ratio1.481.95 (better)
Altman Z-score2.513.07 (better)
Piotroski F-score7 (better)4
Dividends and buybacks
Dividend yield2.2%–
Payout ratio57.1%–
Years of dividend growth9–
Dividend growth, 5Y average8.0%–
Shareholder yield2.2% (better)0.00%
Ownership
Held by institutions82.7%96.2%
Held by insiders0.21%0.21%
Insider net buying, 12 months−$25.7M−$905K (better)
Superinvestors holding–1
Short interest, % of float2.3%3.7%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.